Enveric Biosciences Inc vs KraneShares CSI China Internet ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B). The key difference: KraneShares CSI China Internet ETF is far larger — about 642.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 13,393,361). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and KraneShares CSI China Internet ETF for 57 Days on average.
| ENVB | KWEB | |
|---|---|---|
Market Cap | $6.80M | $4.37B |
Volume | 64,867 | 13,393,361 |
Sector | Health | Sector/Thematic |
52-Week High | $10.80 | $41.35 |
52-Week Low | $1.27 | $23.63 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | -$1.49M | — |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
KWEB trades at $24.93, up 2.47% today but maintains a bearish technical outlook with all 13 moving averages signaling sell. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed sentiment with Tidal Investments reducing its stake by 39.1% while HSBC increased its position by 27.7% in recent quarters.
The China internet ETF remains under pressure from geopolitical tensions and economic rebalancing concerns. While corporate profits surged 26% in Q2 2026, ongoing U.S.-China trade dynamics and potential export curbs create uncertainty. Technical indicators suggest continued bearish momentum with key support at $24.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →